The Nutrition 21 management team is comprised of experts in pharmaceuticals, finance, science, sales and marketing. Their collective expertise positions the organization for continued success in a competitive, ever-changing marketplace.



MICHAEL S. SATOW, CEO

Michael S. Satow has served as CEO since 2011. Michael is responsible for Nutrition 21’s strategic direction and leadership. An entrepreneur, Michael joins Nutrition 21 from JDS Pharmaceuticals, a specialty pharmaceutical company he co-founded which focused on the psychiatry and women’s health markets. Michael served as President and Chief Operating Officer at JDS and successfully sold the company to Noven Pharmaceuticals for $125 million.

Michael began his career as an attorney in private practice and as an enforcement lawyer at the SEC. In 1997, after five years of practicing law, Michael founded and served as CEO of MarketXT, the first retail afterhours stock market, with backing from Morgan Stanley and Salomon Smith Barney. For his work with MarketXT, Michael was named one of the Top 10 American Innovators by US News & World Report. He sold this venture in 2000 for $100 million. From 2000 to 2002, he served as CEO of Mirror Worlds Technologies, a knowledge management software company and the makers of Scopeware.

He currently serves on the board of directors of Houseparty, Inc. and Skymarker LLC. In addition, Michael serves on the boards of The Jed Foundation, a leading charity focused on protecting the mental health of students across the country, and My Sister’s Place, Westchester’s primary domestic violence agency.

Michael received a BA from Columbia College and a JD from the Georgetown University Law Center.


PHILLIP M. SATOW, CHAIRMAN

Phillip M. Satow has served as Chairman of the Board of Directors since 2011. Phillip comes to Nutrition 21 with more than 30 years of experience in the pharmaceutical industry. He was Co-founder, Chairman and CEO of JDS Pharmaceuticals, a specialty pharmaceutical company focused on the psychiatry and women’s health markets. Phillip and his son, Michael, grew JDS to more than $30 million in sales in three years, before selling the company to Noven Pharmaceuticals in 2007 for $125 million.

Prior to founding JDS, Phillip served as Executive Vice President of Forest Laboratories, where he oversaw all marketing and sales functions. He also held the position of President of Forest Pharmaceuticals and was a former member of the Forest Board of Directors. At Forest, Phillip built the company’s sales and marketing infrastructure and retired after launching Forest’s first $1 billion product – the anti-depressant Celexa. Prior to joining Forest, he served as Vice President and General Manager of the Wallace Laboratories Division of Carter–Wallace. In addition, he has held a variety of executive positions at Pfizer, including Director of Marketing of Pfizer Laboratories and Vice President of Pfizer Europe. Phillip has also served on the boards of directors of Crucell, Eyetech and Noven, as well as various others.

Phillip received a BA from Columbia College and an MA from Georgetown University.


JOSEPH  J. WEISS, PRESIDENT

Joseph J. Weiss is an accomplished leader with a strong legacy in product and brand development in the nutritional supplement market. Joseph’s top priorities are to accelerate the company’s growth with product innovation, science and branding. He is uniquely qualified to drive the Nutrition 21 business forward as we develop and commercialize important new ingredients for supplements, functional foods and beverages.

Prior to joining Nutrition 21, Joseph was Vice President of Corporate Brands at Vitamin Shoppe, Inc., a multi-channel specialty retailer and manufacturer of nutritional products and was responsible for product development, sourcing, quality and scientific and regulatory affairs. In addition, he was Senior Vice President of Merchandising at GNC.

Joseph holds B.S. in Economics from The Pennsylvania State University, and an MBA in Marketing from the University of Pittsburgh – Joseph M. Katz Graduate School of Business.


WHITNEY K. STEARNS, JR., CFO

Whitney K. Stearns, Jr. is an experienced and broad based financial executive with over 28 years of directly related generics and branded products pharmaceutical industry experience in private, venture backed start-up and publicly (NASDAQ and NYSE) traded companies (URL Pharma, Inc., JDS Pharmaceuticals, LLC, Phytoceutica, Inc., and Schein Pharmaceuticals).  He has directed all financial activities, financings, cash flow, reporting; managed commercial lender, banking, and investment banking relationships; been responsible for a successful NYSE IPO; established financial and business systems from the ground up, including accounting, commercial, clinical tracking, budgeting and financial reporting systems; managed the financial efforts of three successful strategic investor exit transactions (two at over $800 million, one at $125 million); and participated in myriad company and product acquisitions, divestment, and licensing deals.  His successful career has provided him with a deep understanding of how and what needs to be done at each stage of company growth.  Mr. Stearns began his financial career as a CPA with KPMG and rose to the level of audit partner.

Whit received a BS in Accounting from Lehigh University.


JAMES R. KOMOROWSKI, MS, CNS, VP, SCIENTIFIC AND REGULATORY AFFAIRS

James R. Komorowski, has served as Vice President, Scientific and Regulatory Affairs since July 2001. James is responsible for overseeing technical operations and scientific development at Nutrition 21. James served as Director of Technical Services and Product Development from July 1999 to July 2001 and as Senior Manager of Clinical and Regulatory Affairs from July 1997 to July 1999.

Prior to joining Nutrition 21, James spent nine years in the pharmaceutical industry holding project management, clinical research and regulatory affairs positions at Purdue Pharma and Allergan. He also worked for three years as a research associate at New York Hospital for Special Surgery and Memorial Sloan-Kettering Cancer Center.

Over the course of his career, James has completed more than 100 research studies, submitted over 10 regulatory submissions to the FDA and holds over 12 patents.

James received a BA from the State University of New York and an MS from Long Island University and is a Certified Nutritional Specialist.


WILLIAM J. LEVI, VP, STRATEGY AND BUSINESS DEVELOPMENT

William J. Levi has served as Vice President of Operations and Business Development since May 2006. William is responsible for overseeing corporate operations pursuant to business growth and development at Nutrition 21. William joined Nutrition 21 as Business Director of Ingredients in October 2001. He has more than 25 years of general management, senior sales and marketing experience in the food and nutraceutical ingredient industries across North American and International markets.

Prior to joining Nutrition 21, William served as General Manager of the Humko Oils and Specialty Ingredients divisions at ACH Foods, where he was responsible for operations, sales, marketing and technical service functions, and as Director of Sales and Marketing for Abitec Corporation. He began his food industry career in 1977 with Durkee Foods.

William received a BA from the University of Dayton.


JAMES M. KAHN, EXECUTIVE DIRECTOR OF SALES

James joined Nutrition 21 in 2000. Over the course of his career at the company, he has played a role in several different sales functions, including: inside & outside sales, customer service, logistics, inventory control, supply chain, forecasting, sales reporting, and account management. Prior to his current position, he was most recently the Senior Director of New Business Development.

Prior to joining Nutrition 21, James spent 10 years at Fortune 500 companies: IBM Corporation, where he held a position in Finance, and UST Inc., with a position in Sales & Marketing.

James holds a B.B.A. from Pace University’s Lubin School of Business.